EVA: Evista Alendronate Comparison

Phase 4

Completed

• Conditions: Osteoporosis

• Registration Number: NCT00035971
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2002-05-07
• Study First Submitted QC: 2002-05-07
• Study First Posted: 2002-05-08
• Status Verified: 2006-07
• Last Update Submitted: 2006-07-18
• Last Update Posted: 2006-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (4)

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.; 🇺🇸 Pittsburgh, Pennsylvania, United States

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.; 🇨🇦 Saskatoon, Saskatchewan, Canada

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.; 🇺🇸 Madison, Wisconsin, United States

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559 or speak with your personal physician.; 🇺🇸 Temple, Texas, United States